ABSTRACT
A growing body of evidence supports the notion that cardiovascular disease, especially myocardial infarction, may be substantially reduced following estrogen therapy. In the general population the risk of myocardial infarction may be halved during estrogen replacement therapy. Although few have been carried out, secondary prevention trials suggest an even greater benefit (a relative risk of 0.2) in women with a sustained myocardial infarction. In addition, studies have also indicated that women carrying risk factors for cardiovascular disease like smoking or hypertension may also benefit to a greater extent than those without risk factors 1 , 2 .
